PRLD - Prelude Therapeutics gets FDA greenlight for PRT2527 cancer study

Prelude Therapeutics (NASDAQ:PRLD) announces that the U.S. FDA has accepted the Investigational New Drug (IND) application for its precision oncology candidate, PRT2527, which is designed to be a potent and selective CDK9 inhibitor. In preclinical studies, PRT2527 was shown to reduce MCL1 and MYC protein levels and was highly active in preclinical models at well-tolerated doses, the company said. Prelude anticipates beginning a Phase 1 trial of PRT2527 by year-end evaluating escalating doses of intravenous (IV) PRT2527 as a monotherapy in patients with selected solid tumors. "We look forward to providing updates on PRT2527 and our other clinical development programs in 2022,” CEO Kris Vaddi said.

For further details see:

Prelude Therapeutics gets FDA greenlight for PRT2527 cancer study